A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

August 3, 2018

Study Completion Date

August 3, 2018

Conditions

Healthy Subjects

Interventions

DRUG

Clazosentan

Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h

DRUG

Rifampicin

Single i.v. dose of 600 mg rifampicin for 30 min

OTHER

Saline (0.9% sodium chloride)

Single i.v infusion of 500 mL saline for 30 min

Trial Locations (1)

QPS Netherlands B.V., Groningen